ORIONS Money Stocks

[Dobie Lama]

CYTX-at $6.00--------------I can't wait that long.

Cytori Therapeutics Price Target Raised to $6.00 at Roth Capital (CYTX)
January 16th, 2015 • 0 comments • Filed Under • by ABMN Staff
Share on StockTwits
Cytori Therapeutics logoRoth Capital increased their target price on shares of Cytori Therapeutics (NASDAQ:CYTX) from $3.50 to $6.00 in a research note issued on Friday. The firm currently has a “buy” rating on the stock.

Cytori Therapeutics (NASDAQ:CYTX) traded up 5.81% on Friday, hitting $0.4698. 880,134 shares of the company’sstock traded hands. Cytori Therapeutics has a one year low of $0.36 and a one year high of $3.47. The stock’s 50-day moving average is $0.48 and its 200-day moving average is $1.01. The company’s market cap is $43.4 million.

Cytori Therapeutics (NASDAQ:CYTX) last released its earnings data on Monday, November 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.03.

Separately, analysts at Maxim Group set a $6.00 price target on shares of Cytori Therapeutics and gave the company a “buy” rating in a research note on Friday, December 19th.

Cytori Therapeutics, Inc develops cell therapies based on autologous adipose-derived stem and regenerative cells (NASDAQ:CYTX) to treat cardiovascular disease and repair soft tissue defects. The advanced therapeutic application in the Company’s clinical pipeline is for cardiovascular disease.